TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23412077
Drug: Intensive participants
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive participants who never took insulin or TZD
Study: 23412077
Drug: Intensive participants
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive participants who began insulin or TZD after enrollment
Study: 19941160
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg) for 12 weeks followed by Anastrozole (1 mg) for 12 weeks
Study: 19941160
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg) for 12 weeks followed by Letrozole (2.5 mg) for 12 weeks
Study: 19941160
Drug: Tamoxifen (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (after 6 months of AI therapy)
Study: 19941160
Drug: Prior Tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior Tamoxifen therapy
Study: 1793238
Drug: HeNe laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: HeNe laser treatment (wave-length, 632.8 nm; beam power, 6 mW; continuous emission, energy density, 4 J/cm2)
Study: 1793238
Drug: Placebo HeNe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo HeNe laser treatment
Study: 6430689
Drug: Compliance-improving strategies
Normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Compliance-improving strategies (patient counselling, special medication container, self-recording of medication intake and seizures, mailed reminders)
Study: 30803749
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (4 g daily for 8 weeks)
Study: 29396070
Drug: l-homoarginine (l-hArg)
DrugBank: L-homoarginine (DB03974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-homoarginine (l-hArg) supplementation
Study: 26792024
Drug: Intraduodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal infusion of HCA (2800 mg in water)
Study: 17971533
Drug: Adaptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive treatment strategies
Study: 17971533
Drug: Sequential randomization
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential randomization
Study: 15576850
Drug: PON1 genotypes
Approvals — FDA: no, EMA: no, PMDA: no
Description: PON1 genotypes (L55M, Q192R, -107C/T, -162A/G, -824G/A, and -907G/C)
Study: 8897081
Drug: Sucralfate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (2 g b.i.d. for 5 days)
Study: 1642342
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg intravenous bolus of dexamethasone
Study: 6427477
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg luteinizing hormone releasing hormone agonist daily
Study: 6427477
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg diethylstilbestrol per day
Study: 29327313
Drug: Somatosensory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatosensory therapy (four types of exercises: touch, proprioception, vibration, stereognosis)
Study: 29327313
Drug: Somatosensory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatosensory therapy
Study: 26785711
Drug: Calorie-restricted, semi-vegetarian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie-restricted, semi-vegetarian diet with vitamin D and dietary supplements (fish oil, lipoic acid, omega-3 polyunsaturated fatty acids, resveratrol, multivitamin complex)
Study: 26785711
Drug: Calorie-restricted, semi-vegetarian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie-restricted, semi-vegetarian diet with vitamin D and dietary supplements
Study: 26785711
Drug: Weekly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administration of 5000 IU vitamin D
Study: 2318913
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide suppositories (150 mg)
Study: 2318913
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide (150 mg)
Study: 2318913
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide suppositories
Study: 381860
Drug: Metoprolol (234
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (234 +/- 22 mg/day)
Study: 381860
Drug: Pindolol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (25 +/- 2 mg/day)
Study: 31471863
Drug: BAL101553 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL101553 administered as a 48-h IV infusion at a maximum tolerated dose (MTD) of 70 mg/m2
Study: 31471863
Drug: BAL101553 oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL101553 oral administration on Days 15–21 of cycle 2
Study: 28988746
Drug: Alfaxalone 2
Normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone 2 mg kg−1 (A2)
Study: 28988746
Drug: Alfaxalone 1
Normalized name: alfaxalone 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone 1 mg kg−1 (A1)
Study: 28988746
Drug: Saline 0.1
Normalized name: Simply Saline 0.154 MEQ/ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.1 mL kg−1 (S)
Study: 28988746
Drug: Alfaxalone 1
Normalized name: alfaxalone 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone 1 mg kg−1 (A1) and Alfaxalone 2 mg kg−1 (A2)
Study: 11789085
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg micronized E2 daily
Study: 4147246
Drug: Ro 3‐3528,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 3‐3528, a non‐selective β‐adrenoceptor blocking drug
Study: 28425575
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (9 of 50000 IU cholecalciferol capsules for 9 weeks taken at weekly intervals)
Study: 27979579
Drug: Liraglutide (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (0.6 mg with weekly increase to 3.0 mg for the last week)
Study: 17920501
Drug: Full orthodontic
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full orthodontic treatment (after phase 1)
Study: 7834993
Drug: 6 h
Normalized name: 1-36 hpthrp
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 h primed constant infusion of NaH13CO3 combined with a euglycaemic hyperinsulinaemic clamp for the last 3 h (study 1)
Study: 7834993
Drug: 6 h
Normalized name: 1-36 hpthrp
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 h primed constant infusion of NaH13CO3 alone (study 2)
Study: 7834993
Drug: 6 h
Normalized name: 1-36 hpthrp
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 h infusion of normal saline combined with a hyperinsulinaemic clamp for the last 3 h (study 3)
Study: 3046537
Drug: Inhaled beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta agonist
Study: 30283403
Drug: Melatonin 2
Normalized name: melatonin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 2 mg BD
Study: 30283403
Drug: Melatonin 4
Normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 4 mg BD
Study: 30283403
Drug: Melatonin 8
Normalized name: Calcium Carbonate/Melatonin 84 MG-5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 8 mg BD
Study: 30283403
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of melatonin combined
Study: 27188688
Drug: Mixed-gender Body
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed-gender Body Project (MG)
Study: 24754974
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (systemic and narrative group psychotherapy) with feedback intervention
Study: 24754974
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment only (no feedback)
Study: 24754974
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with feedback intervention
Study: 14964737
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (0.1 mg/kg) with control (saline)
Study: 7524921
Drug: Retroperitoneal lymph-node
Normalized name: Bos taurus lymph preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retroperitoneal lymph-node dissection (RPLND) without adjuvant chemotherapy
Study: 7524921
Drug: Overall survival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall survival with cisplatin-based chemotherapy
Study: 29194180
Drug: No ADL
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ADL retraining in PTA (treatment as usual, TAU)
Study: 24024319
Drug: Dongchongxiacao (Cordyceps)
Normalized name: CORDYCEPS SINENSIS
DrugBank: Ophiocordyceps sinensis (DB19288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dongchongxiacao (Cordyceps) treatment (n = 52)
Study: 24024319
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment (n = 51)
Study: 18412647
Drug: Lidocaine 0.5
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.5 mg x kg(‐1)
Study: 8768815
Drug: Terbinafine cream
Normalized name: terbinafine Topical Cream
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbinafine cream during 1 week
Study: 8768815
Drug: Miconazole cream
Normalized name: Miconazole Nitrate 2% Topical application Cream [CAREALL MICONAZOLE CREAM]
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole cream during 4 weeks
Study: 18308903
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation program (24 hours of computerized practice over a 12-week period and a weekly discussion group)
Study: 15983466
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% amitriptyline
Study: 15983466
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% ketamine
Study: 15983466
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% amitriptyline-1% ketamine combined
Study: 12406832
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 mg chewable tablets)
Study: 10521866
Drug: Screening intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Screening intervention (not specified dosage or duration)
Study: 7723712
Drug: Intracoronary dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary dipyridamole infusion
Study: 7283216
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg epinephrine
Study: 7283216
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg epinephrine
Study: 7283216
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg epinephrine
Study: 20215923
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) treatment
Study: 26054141
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (budesonide nasal spray and cetirizine tablets)
Study: 17556718
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control) for 4 months
Study: 15218357
Drug: Decrease of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease of HER-2/neu ECD levels after three courses of therapy
Study: 2700362
Drug: S +
Normalized name: K-Y Yours + Mine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S + A (PT-01 treatment combined with scaling)
Study: 21402982
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of autologous plasmin enzyme (APE), 0.2 mL
Study: 17038056
Drug: Normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dose of 1% chlorhexidine gel
Study: 17038056
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of chlorhexidine gel and whitening dentifrice
Study: 9068264
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day atenolol
Study: 9068264
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day celiprolol
Study: 9068264
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day isosorbide dinitrate
Study: 3462014
Drug: Cladosporium herbarum
Normalized name: CLADOSPORIUM HERBARUM
DrugBank: Cladosporium herbarum (DB10865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladosporium herbarum inhalation (1:100000, 1:10000, 1:1000, 1:100 w/v)
Study: 3462014
Drug: Histamine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine inhalation (0.3, 0.6, 1.2, 2.4 mg/ml)
Study: 20229169
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg UFT alone (control)
Study: 17660032
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 800 IU of vitamin E alpha daily
Study: 12787300
Drug: fexofenadine 30
Normalized name: fexofenadine 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: fexofenadine 30 mg
Study: 8876706
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg Permixon
Study: 1850811
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy after initial resection
Study: 1850811
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy followed by resection
Study: 1850811
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chemotherapy and radiotherapy (non-surgical patients)
Study: 1850811
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy only (for stage III patients)
Study: 6218789
Drug: Clonidine hydrochloride,
Normalized name: CloNIDine Hydrochloride, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine hydrochloride, 0.05 mg, orally twice daily for two weeks
Study: 30332920
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity testing before chemotherapy and during febrile neutropenia
Study: 30332920
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity testing in patients with documented site of infection
Study: 30332920
Drug: Overall assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall assessment of insulin sensitivity and hospitalization outcome
Study: 26810999
Drug: Daily intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intravenous human albumin solution infusions for up to 14 days or until discharge, based on serum albumin levels.
Study: 22218376
Drug: Single intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular injection of 2.5 mL of low-molecular-weight, non-cross-linked hyaluronic acid
Study: 22218376
Drug: Single intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular injection of 2.5 mL of normal saline solution (placebo)
Study: 7777350
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, n=23)
Study: 2407144
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (bupivacaine 0.25% and fentanyl 2 micrograms/ml, infused at 6-10 ml/h for 76:1.45 h)
Study: 7437747
Drug: Gas-powered jet
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gas-powered jet injection
Study: 20028464
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (sham acupuncture)
Study: 27476252
Drug: Intravenous traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous traditional oxytocin infusion
Study: 25110677
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (1 mL of testosterone enanthate 250 mg/mL) once every four weeks for 12 weeks
Study: 25110677
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL of 0.9% wt/vol NaCl) once every four weeks for 12 weeks
Study: 22392565
Drug: Reduced-dose chemotherapy
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose chemotherapy (elimination of 2 induction drugs and 3 months of maintenance therapy from the standard regimen)
Study: 18809309
Drug: Pattern analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pattern analysis of biomarker molecules from blood samples
Study: 18809309
Drug: Optimized therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized therapy decision based on diagnostic tools
Study: 17315527
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections (MDI) of glargine
Study: 3301155
Drug: Nicardipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (20 or 40 mg t.i.d.)
Study: 26129996
Drug: Culturally Adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally Adapted Cognitive-Behavioral Therapy (CA-CBT)
Study: 23836044
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics (AB) - amoxicillin and metronidazole three times a day for 7 days
Study: 23836044
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) - two applications on the day of SRP and at follow-up after 7 days
Study: 2243674
Drug: Ketorolac ophthalmic
Normalized name: ketorolac ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac ophthalmic solution (NSAID)
Study: 23657629
Drug: Melanoma vaccine
Normalized name: melanoma vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanoma vaccine in incomplete Freund's adjuvant (IFA)
Study: 21177791
Drug: Daily transdermal
Normalized name: Deponit 0.2 MG/HR Daily Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily transdermal DHT gel
Study: 19725341
Drug: Fascia iliaca
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia iliaca compartment block with 0.45% ropivacaine at a dosage of 0.3 mL/kg (maximum dose, 30 mL)
Study: 17623694
Drug: Iclaprim (AR-100)
Normalized name: iclaprim
DrugBank: Iclaprim (DB06358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iclaprim (AR-100) 1.6 mg/kg intravenous infusion
Study: 7812305
Drug: Fiuggi water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiuggi water (more than 1500 ml/die) for 7 and 14 days
Study: 7812305
Drug: Fiuggi water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiuggi water (less than 1500 ml/die) for 7 and 14 days
Study: 2978287
Drug: Protein meal
Normalized name: REAL FOOD BLENDS Select High Protein Meal 1.6 Cal/mL Enteral Suspension (Turkey Pear Pumpkin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein meal (1-1.5 g of protein/kg)
Study: 20694508
Drug: Family Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Cognitive-Behavioral Therapy (FCBT)
Study: 16879931
Drug: Gabapentin 3200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 3200 mg/day
Study: 16879931
Drug: Cocaine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0, 12, 25, 50 mg)
Study: 16879931
Drug: Gabapentin 0
Normalized name: Capsaicin/Menthol/Methyl Salicylate;Gabapentin 0.0375%-5%-20%; 300 MG Multiple Routes Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 0 mg/day (placebo)
Study: 15319143
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Mg++ daily (group A)
Study: 15319143
Drug: No supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplement (group B)
Study: 7923309
Drug: Benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 10 mg twice daily (increased to 20 mg twice daily if necessary)
Study: 3044508
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cholestyramine and bezafibrate
Study: 31974533
Drug: Riociguat treatment
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riociguat treatment after 5 months
Study: 31974533
Drug: Riociguat treatment
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riociguat treatment after 11.2 months
Study: 28126491
Drug: Non-nutritive sweetened
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nutritive sweetened beverage (NSB; sucralose; 4 g)
Study: 28126491
Drug: Sugar-sweetened beverage
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-sweetened beverage (SSB; sucrose; 31 g)